BMEZ · BlackRock Health Sciences Term Trust · Fund Holdings
Market Cap
$995.02M
Shares
62.50M
Volume · Nov 19
211.54K
Avg daily vol (3M)
158.97K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Portfolio holdings reported by registered funds to the SEC on Form N-PORT — the individual securities a fund owns. Only mutual funds, ETFs and closed-end funds file N-PORT, so operating companies show no data.
BlackRock Health Sciences Term Trust
Reported 2026-06-30Net Assets
$1,077,270,525
Total Assets
$1,085,594,062
Holdings
175
Filed
2026-08-25
Securities-lending collateral: 1 row, $2,804,372 (0.26% of net assets). The report marks these as cash received from borrowers of the fund's securities and reinvested, not as positions the fund chose.
| Holding | CUSIP | Balance | Units | Value | % Net Assets | Category | Country |
|---|---|---|---|---|---|---|---|
| Moderna Inc | 60770K107 | 549,814 | NS | $38,503,474 | 3.57% | EC | US |
| Johnson & Johnson | 478160104 | 145,639 | NS | $36,987,937 | 3.43% | EC | US |
| Merck & Co Inc | 58933Y105 | 252,501 | NS | $32,446,379 | 3.01% | EC | US |
| Biogen Inc | 09062X103 | 137,487 | NS | $29,705,441 | 2.76% | EC | US |
| PsiQuantum Corp | 000000000 | 571,947 | NS | $27,619,321 | 2.56% | EC | US |
| Gilead Sciences Inc | 375558103 | 214,745 | NS | $27,130,883 | 2.52% | EC | US |
| Edwards Lifesciences Corp | 28176E108 | 277,879 | NS | $25,136,934 | 2.33% | EC | US |
| Neurocrine Biosciences Inc | 64125C109 | 127,517 | NS | $21,491,078 | 1.99% | EC | US |
| Novartis AG | 000000000 | 136,779 | NS | $21,377,505 | 1.98% | EC | CH |
| Amgen Inc | 031162100 | 57,154 | NS | $20,696,606 | 1.92% | EC | US |
| Illumina Inc | 452327109 | 116,338 | NS | $20,455,711 | 1.90% | EC | US |
| Roche Holding AG | 000000000 | 46,443 | NS | $19,092,079 | 1.77% | EC | CH |
| Thermo Fisher Scientific Inc | 883556102 | 34,802 | NS | $17,448,331 | 1.62% | EC | US |
| AbbVie Inc | 00287Y109 | 67,970 | NS | $17,103,971 | 1.59% | EC | US |
| Genmab A/S | 000000000 | 58,159 | NS | $15,944,419 | 1.48% | EC | DK |
| Axsome Therapeutics Inc | 05464T104 | 62,902 | NS | $15,396,523 | 1.43% | EC | US |
| Danaher Corp | 235851102 | 79,322 | NS | $15,109,255 | 1.40% | EC | US |
| Agilent Technologies Inc | 00846U101 | 112,566 | NS | $14,952,142 | 1.39% | EC | US |
| Natera Inc | 632307104 | 52,122 | NS | $14,148,517 | 1.31% | EC | US |
| BlackRock Liquidity Funds | 09248U718 | 13,962,826 | NS | $13,962,826 | 1.30% | STIV | US |
| Cytokinetics Inc | 23282W605 | 162,568 | NS | $13,849,168 | 1.29% | EC | US |
| Charles River Laboratories International Inc | 159864107 | 60,883 | NS | $13,807,656 | 1.28% | EC | US |
| UnitedHealth Group Inc | 91324P102 | 32,974 | NS | $13,704,984 | 1.27% | EC | US |
| GSK PLC | 000000000 | 521,765 | NS | $13,697,832 | 1.27% | EC | GB |
| Guardant Health Inc | 40131M109 | 89,770 | NS | $13,468,193 | 1.25% | EC | US |
| UCB SA | 000000000 | 44,287 | NS | $13,258,246 | 1.23% | EC | BE |
| Revolution Medicines Inc | 76155X100 | 69,377 | NS | $12,992,925 | 1.21% | EC | US |
| Sartorius AG | 000000000 | 47,229 | NS | $12,390,459 | 1.15% | EP | DE |
| ADARX PHARMACEUTICALS INC | 000000000 | 860,577 | NS | $12,185,770 | 1.13% | EC | US |
| Bio-Techne Corp | 09073M104 | 169,594 | NS | $11,981,816 | 1.11% | EC | US |
| Dexcom Inc | 252131107 | 173,259 | NS | $11,668,994 | 1.08% | EC | US |
| Exelixis Inc | 30161Q104 | 210,176 | NS | $11,435,676 | 1.06% | EC | US |
| Immunocore Holdings PLC | 45258D105 | 359,126 | NS | $11,402,251 | 1.06% | EC | GB |
| Rhythm Pharmaceuticals Inc | 76243J105 | 101,573 | NS | $11,277,650 | 1.05% | EC | US |
| Argenx SE | 04016X101 | 11,933 | NS | $11,071,079 | 1.03% | EC | NL |
| AstraZeneca PLC | 000000000 | 57,869 | NS | $10,973,120 | 1.02% | EC | GB |
| Pfizer Inc | 717081103 | 441,187 | NS | $10,623,783 | 0.99% | EC | US |
| Vertex Pharmaceuticals Inc | 92532F100 | 20,900 | NS | $10,381,657 | 0.96% | EC | US |
| Bristol-Myers Squibb Co | 110122108 | 177,819 | NS | $10,245,931 | 0.95% | EC | US |
| Boston Scientific Corp | 101137107 | 239,074 | NS | $10,203,678 | 0.95% | EC | US |
| GENESIS THERAPEUTICS INC | 000000000 | 1,370,506 | NS | $10,128,039 | 0.94% | EC | US |
| IQVIA Holdings Inc | 46266C105 | 46,747 | NS | $9,032,455 | 0.84% | EC | US |
| Alkermes PLC | 000000000 | 166,685 | NS | $8,733,461 | 0.81% | EC | IE |
| Cogent Biosciences Inc | 19240Q201 | 221,514 | NS | $8,572,592 | 0.80% | EC | US |
| Roivant Sciences Ltd | 000000000 | 240,456 | NS | $8,509,738 | 0.79% | EC | BM |
| Protagonist Therapeutics Inc | 74366E102 | 68,855 | NS | $8,440,246 | 0.78% | EC | US |
| Lonza Group AG | 000000000 | 12,000 | NS | $8,095,249 | 0.75% | EC | CH |
| LARONDE INC | 000000000 | 482,077 | NS | $8,045,865 | 0.75% | EC | US |
| NUMAB THERAPEUTICS AG | 000000000 | 1,139,305 | NS | $8,037,176 | 0.75% | EC | CH |
| Eisai Co Ltd | 000000000 | 304,900 | NS | $7,685,994 | 0.71% | EC | JP |
Showing 1–50 of 175 holdings
Key facts
CIK
1785971
CUSIP
09260E105
13F (30d)
99 filings
83 filers